Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
As someone whose body doesn’t make enough dopamine, food is one of the few things that gives me the hit I need to keep going consistently. There’s enough variety that in my almost forty years on this earth I haven’t found an end to what I enjoy.
So yes, I’m fat and I eat too much, but for me it’s better than being miserable.